In vitro comparative activity of the new beta-lactamase inhibitor taniborbactam with cefepime or meropenem against Klebsiella pneumoniae and cefepime against Pseudomonas aeruginosa metallo-beta-lactamase-producing clinical isolates
Joseph Meletiadis(National and Kapodistrian University of Athens), Spyros Pournaras(National and Kapodistrian University of Athens), Aikaterini Michelaki(General Hospital of Athens G. Genimatas), S. Vourli, Stavroula Antonopoulou(General Hospital of Athens G. Genimatas), Eleni Vagiakou(General Hospital of Athens G. Genimatas), Panagiota‐Christina Georgiou(National and Kapodistrian University of Athens), Paschalis Paranos(National and Kapodistrian University of Athens)
Cited by 33
Related Papers
Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium
|The Lancet Infectious Diseases|2019|1.7k
Infections Caused by<i>Scedosporium</i>spp
|Clinical Microbiology Reviews|2008|757
Effect of appropriate combination therapy on mortality of patients with bloodstream infections due to carbapenemase-producing Enterobacteriaceae (INCREMENT): a retrospective cohort study
|The Lancet Infectious Diseases|2017|521
Global evolution of multidrug-resistant Acinetobacter baumannii clonal lineages
|International Journal of Antimicrobial Agents|2012|502
Predictors of mortality in patients with bloodstream infections caused by KPC-producing Klebsiella pneumoniae and impact of appropriate antimicrobial treatment
|Clinical Microbiology and Infection|2011|441